Celltrion Sets Out Plans To Trial Coronavirus Treatments
Also Expects To Supply UK With Rapid Antibody Tests In Q2
In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.
You may also be interested in...
The European Commission has granted an extension to Celltrion’s pan-European marketing authorization for subcutaneous biosimilar infliximab, which now covers indications for IBD and ankylosing spondylitis.
Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.
Chosen for its existing effective role in treating autoimmune and inflammatory conditions, as well as its well-established safety profile, Celltrion’s infliximab anti-TNF biosimilar is to be used in the UK’s CATALYST trial program to treat COVID-19 patients.